<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Biochemical and clinical features of the mucopolysaccharidoses</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Biochemical and clinical features of the mucopolysaccharidoses</h1>
<div class="graphic"><div class="figure"><div class="ttl">Biochemical and clinical features of the mucopolysaccharidoses</div><div class="cntnt"><table cellspacing="0"><colgroup span="8" width="12"></colgroup> <tbody> <tr> <td class="subtitle1">Type</td> <td class="subtitle1">Common name</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">Enzyme deficient</td> <td class="subtitle1">Genes</td> <td class="subtitle1">Substrate accumulated</td> <td class="subtitle1">Usual age at diagnosis</td> <td class="subtitle1">Key distinct findings</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Skeletal disease, soft tissue storage, and a range of CNS disease</td> </tr> <tr> <td class="indent1" rowspan="3">MPS I</td> <td>Hurler (severe)</td> <td rowspan="3">AR</td> <td rowspan="3">Alpha-L-iduronidase</td> <td rowspan="3"><em>IDUA</em></td> <td rowspan="3">Heparan sulfate, dermatan sulfate</td> <td>1 to 2 years</td> <td>Developmental delay, severe coarse facies, hepatosplenomegaly, airway obstruction, dysostosis multiplex, often placid and loving, death by age 10 years</td> </tr> <tr> <td>Hurler-Scheie (intermediate)</td> <td>1 to 5 years</td> <td>Micrognathia, toe walking, moderate coarse facies, possible normal intelligence, death by 20s</td> </tr> <tr> <td>Scheie (least severe form)</td> <td>3 to 15 years</td> <td>Aortic valve, joint disease, corneal clouding, normal facies, death in decades</td> </tr> <tr> <td class="indent1" rowspan="2">MPS II</td> <td>Hunter (severe)</td> <td rowspan="2">X linked</td> <td rowspan="2">Iduronate sulfatase</td> <td rowspan="2"><em>IDS</em></td> <td rowspan="2">Heparan sulfate, dermatan sulfate</td> <td>1 to 3 years</td> <td>No corneal clouding, physical disease similar to MPS I, aggressive behavior and developmental delay</td> </tr> <tr> <td>Hunter (mild)</td> <td>1 to 5 years</td> <td>Normal or near-normal intelligence</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="3">MPS VII</td> <td>Sly</td> <td class="divider_bottom" rowspan="3">AR</td> <td class="divider_bottom" rowspan="3">Beta-glucuronidase</td> <td class="divider_bottom" rowspan="3"><em>GUSB</em></td> <td class="divider_bottom" rowspan="3">Heparan sulfate, dermatan sulfate</td> <td>Birth to 5 years</td> <td>Variable intermediate presentation similar to MPS I, death in teens</td> </tr> <tr> <td>Fetal hydrops</td> <td>In utero to birth</td> <td>Hydrops in utero, lethal</td> </tr> <tr class="divider_bottom"> <td>Mild</td> <td>Teens to 20s</td> <td>Mild skeletal disease with death in decades</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Skeletal disease and soft tissue storage without CNS disease</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="2">MPS VI</td> <td>Maroteaux-Lamy (severe)</td> <td class="divider_bottom" rowspan="2">AR</td> <td class="divider_bottom" rowspan="2">N-acetylgalactosamine-4-sulfatase (arylsulfatase B)</td> <td class="divider_bottom" rowspan="2"><em>ARSB</em></td> <td class="divider_bottom" rowspan="2">Dermatan sulfate</td> <td>1 to 5 years</td> <td>Like MPS I without CNS disease, pachymeningitis cervicalis, death in teens and 20s, can have corneal clouding</td> </tr> <tr class="divider_bottom"> <td>Maroteaux-Lamy (mild)</td> <td>3 to 12 years</td> <td>Death in decades</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Skeletal, cartilage, and ligament disease primarily; no CNS disease</td> </tr> <tr> <td class="indent1">MPS IV A</td> <td>Morquio type A</td> <td class="divider_bottom" rowspan="3">AR</td> <td>N-acetylgalactosamine-6-sulfatase</td> <td><em>GALNS</em></td> <td rowspan="2">Keratan sulfate</td> <td rowspan="2">1 to 5 years for severe forms</td> <td>Skeletal disease (similar to spondyloepiphysial dysplasia) with short stature, hip dysplasia, scoliosis, ligamentous laxity, corneal opacities</td> </tr> <tr> <td class="indent1">MPS IV B </td> <td>Morquio type B</td> <td>Beta-galactosidase</td> <td><em>GLB1</em></td> <td>Skeletal disease with short stature</td> </tr> <tr class="divider_bottom"> <td class="indent1">MPS IX</td> <td>Natowicz syndrome</td> <td>Hyaluronidase</td> <td><em>HYAL1</em></td> <td>Hyaluronan</td> <td>Only 1 case reported</td> <td>Nodular synovium, popliteal cyst, large-joint effusion</td> </tr> <tr> <td class="subtitle2_left" colspan="8">CNS disease primarily, with less skeletal and soft-tissue disease</td> </tr> <tr> <td class="indent1">MPS III A</td> <td>Sanfilippo A</td> <td rowspan="4">AR</td> <td>Heparan N-sulfatase</td> <td><em>SGSH</em></td> <td rowspan="4">Heparan sulfate</td> <td rowspan="4">2 to 6 years</td> <td rowspan="4">Aggressive behavior followed by progressive neurologic decline</td> </tr> <tr> <td class="indent1">MPS III B</td> <td>Sanfilippo B</td> <td>Alpha-N-acetylglucosaminidase</td> <td><em>NAGLU</em></td> </tr> <tr> <td class="indent1">MPS III C</td> <td>Sanfilippo C</td> <td>Heparan sulfate acetyl-CoA: alpha-glucosaminide N-acetyltransferase</td> <td><em>HGSNAT</em></td> </tr> <tr> <td class="indent1">MPS III D</td> <td>Sanfilippo D</td> <td>N-acetylglucosamine-6-sulfatase</td> <td><em>GNS</em></td> </tr> </tbody></table></div><div class="graphic_footnotes">CNS: central nervous system; MPS: mucopolysaccharidoses; AR: autosomal recesssive; <em>IDUA</em>: iduronidase alpha-L-; <em>IDS</em>: iduronate 2-sulfatase; <em>GUSB</em>: glucuronidase beta; <em>ARSB</em>: arylsulfatase B; <em>GALNS</em>: galactosamine (N-acetyl)-6-sulfatase; <em>GLB1</em>: galactosidase beta 1; <em>HYAL1</em>: hyaluronidase 1; <em>SGSH</em>: N-sulfoglucosamine sulfohydrolase; <em>NAGLU</em>: N-acetyl-alpha-glucosaminidase; CoA: coenzyme A; <em>HGSNAT</em>: heparan-alpha-glucosaminide N-acetyltransferase; <em>GNS</em>: glucosamine (N-acetyl)-6-sulfatase.</div><div id="graphicVersion">Graphic 57733 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
